US FDA Approves FoundationOne®CDx and FoundationOne®Liquid CDx as Companion Diagnostics for TALZENNA® (talazoparib) in Combination with XTANDI® (enzalutamide) to Identify Patients with HRR ...
New data with longer-term follow-up suggest that PSA screening probably lowers prostate cancer mortality — but experts stress ...
"ASCO26: Talzenna and Xtandi combo has first-line promise in HRR altered-mCSPC" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
Wolinsky is a Chicago-based medical journalist and publisher of The Active Surveillor, a Substack newsletter that covers lower-risk prostate cancer and active surveillance. In 2002, at age 55, I ...
Editor's note: Dr. Jamin Brahmbhatt is a urologist and robotic surgeon with Orlando Health and an assistant professor at the University of Central Florida’s College of Medicine.When I learned that ...
The NHS will not be automatically inviting all men above a certain age to check for prostate cancer, unlike the approach for some other cancers. The UK National Screening Committee has suggested that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results